|
|
The Oncologist: Cancer Incidence in First and Second Degree Relatives of BRCA1 and BRCA2 Mutation Carriers
Learning Objectives:
1. Discuss known risks of cancers in BRCA1 and BRCA2 mutation carriers.
2. Cite data from a single institution regarding other cancers described in families of known BRCA mutation carriers.
Background.
Mutations in the BRCA1 and BRCA2 genes are associated with increased risk of breast, ovarian, and several other cancers. The purpose of the present study was to evaluate the incidence of cancer in first- and second-degree relatives of BRCA mutation carriers compared wi... |
|
|
But I Don't Dispense Those! A Community Pharmacist's Guide to Immuno-Oncology Agents
The promise of the immune system in helping to treat cancer has finally become a reality in the past few years. The immune system is designed to differentiate between normal cells foreign cells. To do this, it uses “checkpoints” – molecules on certain immune cells that need to be activated (or inactivated) to start an immune response. Cancer cells often may look like normal cells and may evade the immune system recognition. An important molecule in this process is CTLA4 and thus a CT... |
|
|
Pathology CME Online Bundle: Three Review Programs - Journal Summaries - $1,000 Amazon.com Gift Card
The Pathology CME Online Bundle features:
• From CMEinfo - Three specialty reviews with 49 lectures covering topics in dermatopathology, gastrointestinal and breast pathology
• From Practical Reviews - A one-year subscription, including the FREE mobile app
• A $1,000 Amazon.com gift card
Topics include:
Melanoma, Neoplastic Dermatopathology, Alopecia, Melanocytic Lesions, B cell Lymphomas, Nonneoplastic Colorectal Pathology, Polyposis Syndromes, Small Intestinal Neoplasms, Invas... |
|
|
But I Don't Dispense Those! A Community Pharmacist's Guide to Immuno-Oncology Agents
The promise of the immune system in helping to treat cancer has finally become a reality in the past few years. The immune system is designed to differentiate between normal cells foreign cells. To do this, it uses “checkpoints” – molecules on certain immune cells that need to be activated (or inactivated) to start an immune response. Cancer cells often may look like normal cells and may evade the immune system recognition. An important molecule in this process is CTLA4 and thus a CT... |
|
|
Scale, Bail, or Fail – The CDK4/6 Inhibition Edition
Preclinical and clinical findings suggest that CDK4/6 inhibition may confer therapeutic benefits in numerous tumor types and improve outcomes in patients with mantle cell lymphoma, liposarcoma, melanoma, and non–small cell lung cancer. Additionally, studies of CDK4/6 inhibition of cancers of the prostate, lung, skin, and central nervous system are currently under way.
In the format of an entertaining (but challenging!) interactive game, this edition of Scale, Bail or Fail presents and dis... |
|
|
But I Don't Dispense Those! A Community Pharmacist's Guide to Immuno-Oncology Agents
The promise of the immune system in helping to treat cancer has finally become a reality in the past few years. The immune system is designed to differentiate between normal cells foreign cells. To do this, it uses “checkpoints” – molecules on certain immune cells that need to be activated (or inactivated) to start an immune response. Cancer cells often may look like normal cells and may evade the immune system recognition. An important molecule in this process is CTLA4 and thus a CT... |
|
|
But I Don't Dispense Those! A Community Pharmacist's Guide to Immuno-Oncology Agents
The promise of the immune system in helping to treat cancer has finally become a reality in the past few years. The immune system is designed to differentiate between normal cells foreign cells. To do this, it uses “checkpoints” – molecules on certain immune cells that need to be activated (or inactivated) to start an immune response. Cancer cells often may look like normal cells and may evade the immune system recognition. An important molecule in this process is CTLA4 and thus a CT... |
|
|
But I Don't Dispense Those! A Community Pharmacist's Guide to Immuno-Oncology Agents
The promise of the immune system in helping to treat cancer has finally become a reality in the past few years. The immune system is designed to differentiate between normal cells foreign cells. To do this, it uses “checkpoints” – molecules on certain immune cells that need to be activated (or inactivated) to start an immune response. Cancer cells often may look like normal cells and may evade the immune system recognition. An important molecule in this process is CTLA4 and thus a CT... |
|
|
The Oncologist: Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based Analysis
Learning Objectives:
1. Explain prevalent standards of therapy in Waldenström macroglobulinemia in the United States.
2. Describe changes in the presentation, treatment, and survival of older patients with Waldenström macroglobulinemia over the past 15 years.
3. Develop a balanced concept of value associated with novel therapies in Waldenström macroglobulinemia in the context of their potential survival benefits and costs.
Introduction.
Waldenström macroglobulinemia/lymphoplasmacyti... |
|
|
But I Don't Dispense Those! A Community Pharmacist's Guide to Immuno-Oncology Agents
The promise of the immune system in helping to treat cancer has finally become a reality in the past few years. The immune system is designed to differentiate between normal cells foreign cells. To do this, it uses “checkpoints” – molecules on certain immune cells that need to be activated (or inactivated) to start an immune response. Cancer cells often may look like normal cells and may evade the immune system recognition. An important molecule in this process is CTLA4 and thus a CT... |
|
|
But I Don't Dispense Those! A Community Pharmacist's Guide to Immuno-Oncology Agents
The promise of the immune system in helping to treat cancer has finally become a reality in the past few years. The immune system is designed to differentiate between normal cells foreign cells. To do this, it uses “checkpoints” – molecules on certain immune cells that need to be activated (or inactivated) to start an immune response. Cancer cells often may look like normal cells and may evade the immune system recognition. An important molecule in this process is CTLA4 and thus a CT... |
|
|
But I Don't Dispense Those! A Community Pharmacist's Guide to Immuno-Oncology Agents
The promise of the immune system in helping to treat cancer has finally become a reality in the past few years. The immune system is designed to differentiate between normal cells foreign cells. To do this, it uses “checkpoints” – molecules on certain immune cells that need to be activated (or inactivated) to start an immune response. Cancer cells often may look like normal cells and may evade the immune system recognition. An important molecule in this process is CTLA4 and thus a CT... |
|
|
Evidence-based Updates in Non-Hodgkin’s Lymphoma
Significant advances in treatment with novel agents for B-cell non-Hodgkin’s lymphoma (NHL) have improved patient outcomes and survival. However, many patients are at high-risk of relapse, meriting a precision approach to reduce the rate of recurrence and improve outcomes. The identification of molecular subtypes, the persistence of clinical challenges, and the anticipated emergence of clinical data necessitate a collaborative treatment approach to ensure individualized care for patients wit... |
|
|
Penn Radiology Oncologic Imaging: Optimizing Patient Care (Streaming Online & DVD-ROM)
Penn Radiology joins forces with its experts in Nuclear Medicine, Gastroenterology, Pulmonology, Radiation and Interventional Oncology to present this comprehensive review of Oncologic Imaging. Best practices and clinical correlates will be discussed, with two detailed sessions dedicated to CT screening for lung cancer. Credits for this program can be applied toward your Self Assessment CME Requirements for ABR Maintenance of Certification.
Topics: CT Screening for Lung Cancer, State of th... |
|
|
Penn Radiology Oncologic Imaging: Optimizing Patient Care
Meetings by Mail presents Penn Radiology Oncologic Imaging: Optimizing Patient Care. This comprehensive review of Oncologic Imaging features discussions regarding best practices and clinical correlates, with two detailed sessions dedicated to CT screening for lung cancer.
Other topics include: state of the art and emerging techniques, head and neck cancer, thoracic, GI and other abdominal Malignancies, neuroendocrine tumors, lymphoma, melanoma and MSK. Available in Online Streaming and DVD... |
|
|
The Brigham Board Review in Hematology
Topics covered by The Brigham Board Review in Hematology include:
Hematopoietic Stem Cell Transplantation, Acute Leukemia, Myelodysplastic Syndromes, Myeloproliferative Syndromes, Hodgkin's Lymphoma, Bone Marrow Failure, Hemophagocytic Syndromes, Sickle Cell Disease, Thalassemia and many others.
After completing The Brigham Board Review in Hematology, you will be able to:
• Apply current/recommended Hematology guidelines in clinical practice
• Perform differential diagnosis of comple... |
|
|
The Brigham Board Review in Hematology and Oncology
Get ready for the ABIM exam in Hematology-Oncology by studying this Brigham Board Review in Hematology and Oncology.
Topics covered by the Brigham Board Review in Hematology and Oncology include:
Molecular Genetics of Cancer, Cancer Drug Development, Hematopoietic Stem Cell Transplantation, Acute Leukemias, Myelodysplastic Syndrome, Multiple Myeloma, Hodgkin's Lymphoma, B Cell Malignancies, Mesothelioma, Thyroid Cancer and dozens of others.
After completing the Brigham Board Review in Hemat... |
|
|
Radiation Oncology - A Comprehensive Review: Oakstone Clinical Update
Topics covered in Radiation Oncology include: New Modalities, Central Nervous System Tumors, Head and Neck Tumors, Thoracic Tumors, Upper Gastrointestinal Tumors, Liver Stereotactic Body Radiation Therapy, Soft Tissue Sarcomas. Lymphomas and many others.
After studying Radiation Oncology, you will be better able to:
• Define the initial clinical evaluation of a patient - using physical exam, history, relevant diagnostic studies, and communication with referring and other physicians involve... |
|
|
Clinical Competence in Breast MR, vol. 2
Clinical Competence in Breast MR, vol. 2 contains 100 new comprehensive Breast MR cases, including patient histories, hundreds of images, dynamic sequences and detailed explanations.†The case review explores the many indications for malignant and benign disease, featuring nodules, tumors and patterns of enhancement encountered in every day practice. ††Lectures in indications, techniques and the recognition and report of Breast cancer are also included.. This course meets the case require... |
|
|
Osler Radiation Oncology Online Review
The Osler Institute utilized state of the art equipment to record the comprehensive Radiation Oncology Review Course and bring it to you! These audio files are stored “in the cloud” so you can stream them anywhere, anytime, as long as you have an internet connection – your learning experience is almost like being at the live activity, but without travel costs and time away from your practice. The Osler Radiation Oncology Review also offers a variety of live Radiation Oncology board revie... |
|
|
Osler Surgery MOC Online Review
The Osler Institute utilized state of the art equipment to record the comprehensive Radiation Oncology Review Course and bring it to you! These audio files are stored “in the cloud” so you can stream them anywhere, anytime, as long as you have an internet connection – your learning experience is almost like being at the live activity, but without travel costs and time away from your practice. The Osler Radiation Oncology Review also offers a variety of live Radiation Oncology board revie... |
|